CN117165520A - 间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 - Google Patents
间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 Download PDFInfo
- Publication number
- CN117165520A CN117165520A CN202311158885.3A CN202311158885A CN117165520A CN 117165520 A CN117165520 A CN 117165520A CN 202311158885 A CN202311158885 A CN 202311158885A CN 117165520 A CN117165520 A CN 117165520A
- Authority
- CN
- China
- Prior art keywords
- experimental group
- group iii
- control group
- exosome
- experimental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 186
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 17
- 208000003351 Melanosis Diseases 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims description 117
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 34
- 239000001963 growth medium Substances 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 17
- 229930182816 L-glutamine Natural products 0.000 claims description 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 17
- 229930003268 Vitamin C Natural products 0.000 claims description 17
- 229960002897 heparin Drugs 0.000 claims description 17
- 229920000669 heparin Polymers 0.000 claims description 17
- 235000019154 vitamin C Nutrition 0.000 claims description 17
- 239000011718 vitamin C Substances 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000006166 lysate Substances 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 10
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 claims description 8
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 102100027221 CD81 antigen Human genes 0.000 claims description 7
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 7
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 7
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 7
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102100025222 CD63 antigen Human genes 0.000 claims description 6
- 102100037904 CD9 antigen Human genes 0.000 claims description 6
- 102000034342 Calnexin Human genes 0.000 claims description 6
- 108010056891 Calnexin Proteins 0.000 claims description 6
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 3
- 230000037314 wound repair Effects 0.000 claims description 3
- 239000012888 bovine serum Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 30
- 206010052428 Wound Diseases 0.000 abstract description 27
- 230000029663 wound healing Effects 0.000 abstract description 14
- 210000002950 fibroblast Anatomy 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract description 11
- 210000001519 tissue Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 102000003425 Tyrosinase Human genes 0.000 abstract description 9
- 108060008724 Tyrosinase Proteins 0.000 abstract description 9
- 208000014674 injury Diseases 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 210000002615 epidermis Anatomy 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 206010014970 Ephelides Diseases 0.000 abstract description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 210000004207 dermis Anatomy 0.000 abstract description 3
- 210000001126 granulation tissue Anatomy 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 107
- 239000000243 solution Substances 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 238000011068 loading method Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 230000010100 anticoagulation Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 206010072170 Skin wound Diseases 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000006750 UV protection Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- -1 diphenyl picrylbenzene Chemical compound 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 241000196322 Marchantia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311158885.3A CN117165520B (zh) | 2023-09-08 | 2023-09-08 | 间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311158885.3A CN117165520B (zh) | 2023-09-08 | 2023-09-08 | 间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117165520A true CN117165520A (zh) | 2023-12-05 |
CN117165520B CN117165520B (zh) | 2024-04-26 |
Family
ID=88936069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311158885.3A Active CN117165520B (zh) | 2023-09-08 | 2023-09-08 | 间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117165520B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101834A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Neuro-Science Allies Private Limited | A method for obtaining mesenchymal stem cells, media, methods and composition thereof |
CN106434530A (zh) * | 2016-11-16 | 2017-02-22 | 沈阳细胞治疗工程技术研发中心有限公司 | 一种内皮细胞培养液 |
CN108823156A (zh) * | 2018-07-04 | 2018-11-16 | 陕西神州生物技术有限公司 | 用于修复的临床级人脐带间充质干细胞复合因子及冻干粉的制备方法 |
CN110072534A (zh) * | 2016-10-13 | 2019-07-30 | Vbc控股有限责任公司 | 外泌体的医学应用 |
CN111297900A (zh) * | 2020-05-13 | 2020-06-19 | 优赛生命科技有限公司 | 一种富含脂肪干细胞外泌体的组合物及其应用 |
CN111527199A (zh) * | 2017-11-16 | 2020-08-11 | 得克萨斯大学体系董事会 | 用于制备来源于msc的外泌体的方法 |
CN113717944A (zh) * | 2021-09-03 | 2021-11-30 | 江苏大学 | 一种miRNA13896过表达的工程化人脐带间质干细胞源外泌体及制备方法和应用 |
CN114099547A (zh) * | 2021-12-07 | 2022-03-01 | 洛阳市三启生物技术有限公司 | 一种用于皮肤修复的干细胞外泌体制剂 |
-
2023
- 2023-09-08 CN CN202311158885.3A patent/CN117165520B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101834A1 (en) * | 2010-02-22 | 2011-08-25 | Advanced Neuro-Science Allies Private Limited | A method for obtaining mesenchymal stem cells, media, methods and composition thereof |
CN110072534A (zh) * | 2016-10-13 | 2019-07-30 | Vbc控股有限责任公司 | 外泌体的医学应用 |
CN106434530A (zh) * | 2016-11-16 | 2017-02-22 | 沈阳细胞治疗工程技术研发中心有限公司 | 一种内皮细胞培养液 |
CN111527199A (zh) * | 2017-11-16 | 2020-08-11 | 得克萨斯大学体系董事会 | 用于制备来源于msc的外泌体的方法 |
CN108823156A (zh) * | 2018-07-04 | 2018-11-16 | 陕西神州生物技术有限公司 | 用于修复的临床级人脐带间充质干细胞复合因子及冻干粉的制备方法 |
CN111297900A (zh) * | 2020-05-13 | 2020-06-19 | 优赛生命科技有限公司 | 一种富含脂肪干细胞外泌体的组合物及其应用 |
CN113717944A (zh) * | 2021-09-03 | 2021-11-30 | 江苏大学 | 一种miRNA13896过表达的工程化人脐带间质干细胞源外泌体及制备方法和应用 |
CN114099547A (zh) * | 2021-12-07 | 2022-03-01 | 洛阳市三启生物技术有限公司 | 一种用于皮肤修复的干细胞外泌体制剂 |
Non-Patent Citations (1)
Title |
---|
HEMEDA: "Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells", CYTOTHERAPY, vol. 16, 31 December 2014 (2014-12-31), pages 170 - 180, XP055202535, DOI: 10.1016/j.jcyt.2013.11.004 * |
Also Published As
Publication number | Publication date |
---|---|
CN117165520B (zh) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2711330C2 (ru) | Сывороточная фракция обогащенного тромбоцитами фибрина | |
Aiba‐Kojima et al. | Characterization of wound drainage fluids as a source of soluble factors associated with wound healing: comparison with platelet‐rich plasma and potential use in cell culture | |
US20180099026A1 (en) | Treatment of peripheral vascular disease using protein solutions | |
CN109641013B (zh) | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 | |
US20210260129A1 (en) | Cell Expansion Methods and Therapeutic Compositions | |
JP2021506801A (ja) | 精製されたエクソソーム生成物、作成方法及び使用方法 | |
WO2020061627A1 (en) | Mesenchymal stem cells and products therefrom | |
US20200078411A1 (en) | Biological Scaffolds, Products Containing Biological Scaffolds and Methods of Using the Same | |
Yang et al. | Platelet poor plasma gel combined with amnion improves the therapeutic effects of human umbilical cord‑derived mesenchymal stem cells on wound healing in rats | |
Cheng et al. | Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets | |
WO2016132357A1 (en) | Modified blood clots | |
RU2644650C2 (ru) | Материал стволовых клеток и способ его получения | |
CN117165520B (zh) | 间充质干细胞外泌体、凝胶制剂及在表皮创伤和祛斑中的应用 | |
CN116474000B (zh) | 脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用 | |
Laurens | Development of a new extraction method for platelet-rich plasma and partial purification of platelet-derived growth factor and transforming growth factor beta | |
US20180000869A1 (en) | Amniotic fluid-derived preparations | |
TWI670071B (zh) | 促進毛髮增長或促進毛髮細胞生長的組合物及其用途 | |
AU2021106118A4 (en) | Use of microvesicle derived from umbilical cord mesenchymal stem cell in preparation of formulation for promoting regeneration of post-traumatic skin appendage | |
RU2620342C1 (ru) | Косметическое средство на основе продуктов секреции мезенхимных стволовых/стромальных клеток жировой ткани человека и способ его получения | |
RU2664478C2 (ru) | Способ получения культуральной ростовой добавки на основе лизата тромбоцитов человека | |
RU2665155C1 (ru) | Способ доставки биологически активных веществ в скаффолд | |
CN115040539A (zh) | 一种优化的血小板外泌体冻干粉在糖尿病足溃疡中的应用及其制备方法 | |
CA3223320A1 (en) | Preparation method and container for a topical wound healing gel | |
CN116286664A (zh) | 一种脐带间充质干细胞外泌体的用途 | |
US20190391147A1 (en) | Methods and kits for detecting myo/nog cells in human adipose tissue and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240402 Address after: Building 1-308, Building 14, Left Bank Science and Technology Base, No. 18 Haitai South Road, Huayuan Industrial Zone, High tech Zone, Binhai New Area, Tianjin, 300450 Applicant after: Tianjin Kerong Zhongjian Biotechnology Co.,Ltd. Country or region after: China Address before: Building 1, 5-1, No. 162 Wusan Avenue, Xinzhou District, Shangrao City, Jiangxi Province, 334000 Applicant before: Xiaocao Biotechnology Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |